Paul Fehlner, co-founder and CEO of reVision Therapeutics, Inc., provided an overview of our their program, REV-0100, for Stargardt disease, a rare pediatric retinal disease. REV-0100 has the potential to expand to dry age-related macular degeneration (AMD). During the session, he discussed various aspects of REV-0100, including its mechanism of action, in vivo efficacy in Stargardt mouse models, systemic safety, competitive advantage, and development timeline.
REV-0100 is sulfobutyl-ether-beta-cyclodextrin, a commonly used pharmaceutical excipient now evaluated in this orphan indication.